Immunovative Therapies Overview

  • Founded
  • 2004
Founded
  • Status
  • Private
  • Employees
  • 18
Employees
  • Latest Deal Type
  • 2ndary - Private
  • Latest Deal Amount
  • $5M
Latest Deal Amount
  • Investors
  • 1

Immunovative Therapies General Information

Description

Developer of novel immunotherapy drug products designed to incorporate living immune cells as the active ingredients. The company's products are designed to modulate and control the human immune system in order to direct the power of these natural defenses toward the treatment of cancer and infectious diseases, enabling patients to get cost-effective improved quality of life and curative or life-extending treatment options.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Malcha Technology Park
  • 1 Agudat Sport Hapoel Street, Center
  • Jerusalem 96951
  • Israel
+972 00-000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Immunovative Therapies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Secondary Transaction - Private 01-Apr-2021 $5M 000.00 00000 Completed Clinical Trials - Phase 2
8. Later Stage VC 01-Jan-2015 000.00 000.00 Completed Clinical Trials - Phase 2
7. Later Stage VC 18-Dec-2011 0000 000.00 Completed Clinical Trials - Phase 2
6. Early Stage VC 00.00 00.00 Completed Startup
5. Early Stage VC 07-Jan-2008 00.00 000 Completed Startup
4. Grant 01-Jan-2008 00000 00000 Completed Startup
3. Early Stage VC 01-May-2006 00000 00000 Completed Startup
2. Accelerator/Incubator Completed Startup
1. Early Stage VC 01-May-2004 Completed Startup
To view Immunovative Therapies’s complete valuation and funding history, request access »

Immunovative Therapies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel immunotherapy drug products designed to incorporate living immune cells as the active ingredients. Th
Drug Discovery
Jerusalem, Israel
18 As of 2021
000.00
0000 0000-00-00
00000000000 000.00

00000000

t ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco labor
0000000000000
Ballerup, Denmark
000 As of 0000
00000
000000&0 00000

00 00000

m ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et d
0000 000000000
Copenhagen N, Denmark
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Immunovative Therapies Competitors (38)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Symphogen Formerly VC-backed Ballerup, Denmark 000 00000 000000&0 00000
00 0000000 Venture Capital-Backed Copenhagen N, Denmark 00 00000 00000000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000000 Formerly VC-backed New Haven, CT 000 00000 000000 - 000 00000
00000 000000000000 Formerly VC-backed Waltham, MA 00 00000 00000000 00000
You’re viewing 5 of 38 competitors. Get the full list »

Immunovative Therapies Patents

Immunovative Therapies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2904853-A1 Ablative immunotherapy Pending 12-Mar-2013 000000000
JP-6538647-B2 Ablation immunotherapy Active 12-Mar-2013 0000000000
AU-2014249374-A1 Ablative immunotherapy Abandoned 12-Mar-2013 000000000
JP-2016518319-A Ablation immunotherapy Granted 12-Mar-2013 0000000000
AU-2020201309-A1 Ablative immunotherapy Pending 12-Mar-2013 C12N5/0636

Immunovative Therapies Executive Team (7)

Name Title Board Seat Contact Info
Michael Har-Noy Founder, Chief Executive Officer & Chief Science Officer
You’re viewing 1 of 7 executive team members. Get the full list »

Immunovative Therapies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immunovative Therapies Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Novo Energy Corporation Minority 000 0000 000000 0
To view Immunovative Therapies’s complete investors history, request access »